Insulin-like growth factor-binding protein-3 (IGFBP-3) is an important regulator of insulin-like growth factor (IGF) bioavailability and IGF-independent growth responses.
Introduction
Insulin-like growth factor-I (IGF-I) is an anabolic polypeptide that mediates the growth-promoting effects of growth hormone on skeletal tissues (Jones & Clemmons 1995) . IGF-I also stimulates the proliferation or differentiation of a wide variety of cells, and promotes diverse cell functions. The actions of IGF-I are modulated by at least six distinct insulin-like growth factor-binding proteins (IGFBPs) . Previous studies have shown that platelet alpha granules contain both IGF-I and IGFBP-3 (Karey & Sirbasku 1989 , Spencer et al. 1993 , but that the precursor of platelets, the megakaryocyte, does not express the IGFBP-3 gene (Chan & Spencer 1998) . Chan & Spencer (1998) have further demonstrated that IGF-I and IGFBP-3 are taken up from the extracellular fluid by megakaryocytes and transported into the alpha granules. The alpha granules and other cytoplasmic contents are encapsulated in the platelets when they are formed from the megakaryocyte. Platelet lysis subsequently releases the contents of the alpha granules into tissues.
The mechanism for megakaryocyte incorporation of proteins from the extracellular fluid into the alpha granules is receptor-mediated endocytosis (Steinman et al. 1983 , Behnke 1992 . Studies by Behnke (1989 Behnke ( , 1992 have shown that only material endocytosed into clathrin-coated vesicles is conveyed to the alpha granules. This includes molecules bound to receptors and those passively transported in the fluid phase. The latter can be eliminated for IGFBP-3 because of its high concentration in the alpha granules (George 1990 , Spencer et al. 1993 . Clathrinindependent uptake leads to a lysosomal pathway (Behnke 1992) . IGFBP-3 has been reported to be associated with cell membranes (De Mellow & Baxter 1988 , Conover et al. 1990 ) as well as with receptors (Oh et al. 1993b , Leal et al. 1997 . Since IGFBP-3 can associate with cell membranes, it may be passively transported to the alpha granules in the clathrin-coated pits (De Mellow & Baxter 1988 , Conover et al. 1990 ). To investigate this possibility, studies were performed to determine whether IGFBP-3 binds to human platelet membranes via a specific receptor interaction, and what role IGF-I plays in this process. The identification of an IGFBP-3 receptor on the platelet membrane strongly suggests that the internalisation pathway utilised by megakaryocytes is receptor mediated. This receptor may also activate a signalling cascade, which could be involved in several functions, i.e. transport to the alpha granule, direct growth-inhibitory effects of IGFBP-3, and/or transport into the cytoplasm from which IGFBP-3 may be targeted to the nucleus by virtue of its nuclear targeting sequence.
Materials and Methods

Materials
Bacterially derived recombinant human IGFBP-3 (Escherichia coli IGFBP-3; 28·7 kDa), glycosylated recombinant human IGFBP-3 (43 kDa) and recombinant IGF-I were gifts from Celtrix Laboratories (Santa Clara, CA, USA). Rat IGFBP-4 has been cloned and expressed by Chelius et al. (2000) . Bovine albumin fraction V (A7888), phenylmethylsulphonyl fluoride (PMSF) and N-ethyl maleimide (NEM) were from Sigma (St Louis, MO, USA).
Glycosylated IGFBP-3 was iodinated by the chloramine T method (Spencer et al. 1993 ) to a specific activity of 100 µCi/µg. The free 125 I -was separated from the bound iodine by using Sephadex G-100 (Amersham Pharmacia, Piscataway, NJ, USA). Trace was used within 3 weeks of iodination and was in the monomeric form. Fewer than 5% fragments were apparent after 2 months.
Human platelets were purchased from Blood Centers of the Pacific (San Francisco, CA, USA). Platelets were purified by differential centrifugation of 450 ml anticoagulated whole blood from normal donors, and were used within 72 h of blood collection. Platelet concentrate samples were diluted in Isoton III (Coulter Corporation, Miami, FL, USA) and counted with a Coulter STKS flow cytometer. Yields were typically 45-90 10 9 cells from a unit of blood with less than 1% leukocyte contamination.
Platelet-membrane preparation
Human platelet membranes were prepared by following the method of Varani et al. (1996) , with minor modifications. Platelet concentrates were diluted to 300 ml in buffer A (50 mM Tris, 20 mM EDTA, 150 mM NaCl; pH 7·4 at 25 C) and centrifuged at 17 500 g (15 min, 25 C). The pellet was resuspended to 150 ml in cold hypotonic buffer B (5 mM Tris, 10 mM EDTA, 0·1 mM PMSF, 0·1 mM NEM; pH 7·4 at 4 C) and homogenised with a Polytron homogeniser, using a PT10 head (30 s at 90% power). The platelet membranes were then sedimented (35 000 g, 15 min, 4 C) and washed once (35 000 g, 15 min, 4 C) with 120 ml cold buffer C (50 mM Tris, 0·8 mM EDTA, 0·1 mM PMSF, 0·1 mM NEM; pH 7·4 at 4 C). Washed membranes were resuspended in 25 ml cold buffer D (55·6 mM Tris, 11·1 mM MgCl 2 , 0·1 mM PMSF, 0·1 mM NEM; pH 6·8 at 4 C) and stored at 80 C until required. The protein concentration was quantified with the Bradford assay (Bradford 1976) , using a commercial kit (BioRad, Hercules, CA, USA) with bovine albumin (fraction V) as a reference standard. The membranes contained no detectable IGFBP-3 according to Western blot analysis. Significant binding by extraneous internal platelet membranes was unlikely, as data indicated only a single class of binding site.
Preparation of a human plasma pool
Human plasma was obtained from samples to be discarded after phlebotomy or plasmapheresis. The plasma was separated by gel filtration on a Sephadex G-50 (Amersham Pharmacia) column, equilibrated with 0·5 M acetic acid, to remove IGF-I. Collected fractions (K d =0·09-0·40) were then pooled, dried under vacuum and resuspended in buffer E (9 parts buffer D and 1 part 10% (w/v) BSA) to half of the original plasma volume (yielding a 200% plasma pool). Aliquots were stored at 20 C. The 200% human plasma pool contained 39·8 nM IGFBP-3, as determined by radioimmunoassay. Other IGFBPs were expected to be retained in the plasma pool but were not quantified.
Membrane binding assay
Platelet membranes were thawed, sedimented (35 000 g, 15 min, 4 C) and resuspended in cold buffer E. Membrane suspensions (50 µl) were incubated with 50 µl 125 I-IGFBP-3 and various test substances (100 µl) on a shaking platform at 10 C. The membranes were then sedimented (12 000 g, 3 min) and the pellet was counted to determine the amount of bound radioactivity. Non-specific binding was defined as the amount of radioactivity not displaced by either a 100% plasma pool (when 100 µg membranes were used) or by 6·8 µM E. coli IGFBP-3 (when 10 µg were used).
Kinetic binding assays
Association Membrane suspensions (10 µg) were incubated with 50 µl 125 I-IGFBP-3 on a shaking platform at 10 C for various periods of time (0-120 min). Three minutes prior to the end of each time-point, the membranes were sedimented (12 000 g, 3 min) and the pellets were counted to determine the amount of bound radioactivity. Non-specific binding was determined at each time-point as the amount of radioactivity not displaced by 6·8 µM E. coli IGFBP-3.
Dissociation Membrane suspensions (10 µg) were incubated with 50 µl 125 I-IGFBP-3 on a shaking platform at 10 C for 2 h to reach binding equilibrium. The membranes were then sedimented (12 000 g, 3 min) and each pellet was resuspended in 1·5 ml cold buffer E. Dissociation was allowed to proceed for various periods of time (0-60 min) before the membranes were again sedimented and the pellets counted to determine the amount of radioactivity remaining bound. Non-specific binding was determined at the initial dissociation time-point as the amount of radioactivity not displaced by 6·8 µM E. coli IGFBP-3.
Statistics and analysis
All values are expressed as means ... The equilibrium dissociation constant was calculated by non-linear regression analysis by using a model of one-site binding and adjusting for ligand depletion (; GraphPad Software Inc., San Diego, CA, USA). Kinetic analysis of association binding was performed using a one-phase exponential association equation to determine the observed rate constant (k ob ). The forward rate constant (k on ) was derived from the k ob using the equation: k on =(k ob -k off )/ [ 125 I-IGFBP-3] (Motulsky & Neubig 1997) . The reverse rate constant (k off ) was determined directly from the experimental data using a standard one-phase decay equation. The reverse rate constant was also calculated using the equation K d =k off /k on . Natural logarithmic transformation of the kinetic data was performed to confirm that both the association and the dissociation were first-order reactions. Analysis of competition binding was by one-way ANOVA. Where P<0·05, a Bonferroni post-hoc test was performed (all-group comparison).
Results
Characteristics of IGFBP-3 binding to platelet membranes
The nature of the association between IGFBP-3 and the platelet membrane was investigated by performing binding assays with homogenised platelet-membrane preparations. Preliminary studies indicated that the binding of 125 I-IGFBP-3 to platelet membranes was pH-dependent, optimal binding being observed at pH 6·8. Only minor differences in binding were observed between the 3, 6 and 24 h incubations; thus, initial studies were performed for 6 h to ensure that binding had reached equilibrium.
Two models of binding were established, using either 10 µg or 100 µg platelet membranes per tube. With the reduced number of binding sites available on 10 µg of membranes, non-glycosylated E. coli IGFBP-3 was able to effectively block 149 pM 125 I-IGFBP-3 binding (Fig. 1) . E. coli IGFBP-3 induced a concentration-dependent inhibition of 125 I-IGFBP-3 binding. In studies with 10 µg membranes, the addition of 1·4 nmoles E. coli IGFBP-3 was used to determine non-specific binding, as this concentration produced maximal inhibition of 125 I-IGFBP-3 binding. In early studies using 100 µg membranes, binding of 182 pM 125 I-IGFBP-3 could not be fully inhibited by the addition of a reasonable quantity of unlabelled E. coli IGFBP-3, because of the large number of binding sites present. However, a human plasma pool enriched for IGFBP-3 activity improved assay sensitivity and was able to inhibit binding of both 182 pM and 698 pM 125 I-IGFBP-3 in a dose-dependent manner (results not shown). With both concentrations of 125 I-IGFBP-3 tested, maximal inhibition was observed with a 100% (v/v) human plasma pool, and this concentration was then used to determine non-specific binding in experiments in which 100 µg platelet membranes were used. The binding experiments conducted using either E. coli IGFBP-3 or the plasma pool to determine non-specific binding yielded parallel dose-response curves when inhibitory activity was expressed as a function of IGFBP-3 concentration, even though the experiments were not strictly comparable (because of differences in the 125 I-IGFBP-3 and receptor concentrations tested). Figure 2A shows the relationship between increasing concentrations of 125 I-IGFBP-3 and specific binding to 100 µg platelet membranes. Specific binding could be detected with as little as 9·1 pM radiolabel, and began to saturate near 4·6 nM 125 I-IGFBP-3. In contrast, non- 
Saturability of IGFBP-3 binding
Scatchard transformation
The Scatchard transformation (Fig. 2B ) is a composite of four experimental determinations using 10 µg and 100 µg platelet membranes, in which bound radiolabel was less than 15% of the total 125 I-IGFBP-3 added. As the Scatchard transformation relies on the assumption that receptor binding does not overly deplete the concentration of available radiolabel, data points were included in the transformation only when less than 15% binding was observed. The linearity of the Scatchard plot suggests the presence of a single class of binding sites for 125 I-IGFBP-3 on human platelets, in agreement with the non-linear regression analysis.
Kinetic studies of IGFBP-3 binding to platelet membranes
Specific binding of 233 pM 125 I-IGFBP-3 to platelet membranes was measured over a period of 120 min (Fig. 3) . Binding reached equilibrium within 20 min and had an observed rate constant (k ob ) of 3·5 0·2 10 1 per min (t 1/2 =2·0 min). From the known k ob and K d values, forward (k on ) and reverse (k off ) rate constants were calculated to be 8·1 10 8 per M per min and 1·6 10 1 per min (t 1/2 =4·2 min) respectively. Reversibility of binding was determined using platelet membranes that had been pre-equilibrated with 125 I-IGFBP-3 for 3 h at 10 C. Dissociation of bound 125 I-IGFBP-3 was initiated by removing the buffer and replacing it with fresh buffer containing no radiolabel. Specific binding was measured over a period of 60 min, with near-complete dissociation being evident within 20 min (Fig. 4) . A reverse rate constant of 3·3 0·1 10 1 per min (t 1/2 =2·1 min) was determined experimentally by non-linear regression analysis. This value is in close agreement with that calculated from the K d and k ob parameters. The natural logarithmic transformations in I-IGFBP-3 binding. B/F is the ratio of bound to free radiolabel. Values are the combined results from four separate experiments using either 100 g ( and ) or 10 g ( and ) platelet membranes, with a 100% (v/v) human plasma pool or 6·8 M E. coli IGFBP-3 to determine non-specific binding respectively. Only those data points for which depletion of free 125 I-IGFBP-3 was less than 15% were included. Platelet age is expressed as the time lapsed between the drawing of blood and the storing of prepared membranes at 80 C. 
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Figs 3B and 4B indicated that the reaction shows firstorder kinetics and follows the law of mass action with a single affinity site.
Competitive inhibition of IGFBP-3 binding
IGFBP-4
As small amounts of low-molecular-weight IGFBPs have been reported in alpha-granule lysates from hypophysectomised rats (Chan & Spencer 1998) , we tested the ability of rat IGFBP-4 to compete with IGFBP-3 for binding to 100 µg platelet membranes. Neither E. coli IGFBP-3 nor IGFBP-4 was able to inhibit the binding of 700 pM 
Discussion
This study describes the interaction of IGFBP-3 with novel binding sites on human platelet plasma membranes. Our data show that exogenous IGFBP-3 binds to platelet membranes with high affinity and via a large number of binding sites. IGFBP-3 binding to these membranes was saturable, reversible and fully inhibited by unlabelled IGFBP-3, but not by rat IGFBP-4. These characteristics are indicative of an IGFBP-3 receptor on platelet membranes and, consequently, their precursor megakaryocyte membranes, and extend previous work suggesting the presence of a specific receptor-mediated pathway for the internalisation of extracellular IGFBP-3 into platelet alpha granules (Chan & Spencer 1998) . We also report that co-incubation with large excesses of IGF-I only marginally inhibits IGFBP-3 binding, but not in a dose-dependent manner. This allows the possibility that the IGFBP-3-IGF-I complex may be internalised and transported to the alpha granules.
Platelet purity was essential to the characterisation of a platelet IGFBP-3 receptor, as the presence of specific IGFBP-3 binding sites on other blood-cell populations could not be excluded. However, it is unlikely that the binding characteristics identified in this work could have been attributable to the contaminating leukocyte population (less than 1%). Membranes, rather than whole platelets, were used in these studies to increase the number of experiments that could be performed with material from a single donor. Intact platelets specifically bind IGFBP-3, but they undergo progressive activation and alteration of receptors during routine storage (Rinder & Snyder 1992 , Lozano et al. 1997 . The use of membranes also eliminated the possibility that 125 I-IGFBP-3 or any breakdown products would be pinocytosed by platelets, although the significance of this pathway is disputed (Neyses et al. 1984 , Behnke 1992 . It is unlikely that endogenous IGFBP-3 released from the alpha granules during the process of homogenisation would still be specifically bound to receptors. The rapid dissociation of 125 I-IGFBP-3 from platelet receptors (t 1/2 2-4 min) would remove any bound IGFBP-3 during the many washing and dilution steps involved in membrane preparation. Additionally, no endogenous IGFBP-3 could be extracted from membrane preparations.
Two models were used, employing 10 µg and 100 µg platelet membranes, to study the full range of binding. The non-specific binding for the 10 µg assays was determined by the addition of 6·8 µM E. coli IGFBP-3; for the 100 µg assay, partially purified plasma was used. With either of these models, concentration curves revealed the presence of a single class of saturable binding sites for glycosylated 125 I-IGFBP-3. Non-linear regression analyses showed that the affinity constants and numbers of binding sites varied slightly between platelet membrane preparations, as might be expected with platelets of varying age and from different donors. The variations in receptor affinity observed between platelet donors may also have originated from minor differences in membrane preparation, or because of the presence of an unidentified co-factor able to modulate receptor affinity for IGFBP-3.
The platelet-membrane binding studies used only glycosylated 125 I-IGFBP-3 for all calculations of K d and kinetic variables, since it, rather than the E. coli-derived 28·7 kDa IGFBP-3, is the natural ligand for the receptor. Comparison of the K d with the competition curve established using non-glycosylated IGFBP-3 suggests that the latter has a significantly lower affinity for the receptor. This is in direct contrast with the results reported by Firth & Baxter (1999) for cell association.
There are reports that IGFBP-3 can bind to specific membrane proteins, including the type V transforming growth factor-(TGF ) receptor on mink lung epithelial (Mv1 Lu) cells (Leal et al. 1997 (Leal et al. , 1999 , and to novel low-molecular-weight (20, 26 and 50 kDa) cell association proteins expressed by Hs578T breast cancer cells (Oh et al. 1993b) . The platelet receptor is different from these putative IGFBP-3 receptors. The affinity of IGFBP-3 for the platelet-membrane receptor (K d =2·60 -8·04 10 10 M) is approximately 10 times higher than that reported for the type V TGF receptor (Leal et al. 1997) and the proteins on Hs578T and MCF-7 breast cancer cells (Yamanaka et al. 1999) . Also, neither IGF-I nor IGFBP-4 affects the association of IGFBP-3 with the platelet receptor.
The modulatory effect of IGF-I on IGFBP-3 binding highlights a fundamental difference between the platelet receptor and putative IGFBP-3 receptors on other cell types. Binding of IGFBP-3 to the reported type V TGF receptor induces growth inhibition in Mv1 Lu cells (Leal et al. 1997) , while binding to specific cell association proteins produces a similar response in Hs578T cells (Oh et al. 1993a ). The addition of IGF peptides diminishes this inhibition, probably through the formation of IGF-IGFBP-3 complexes that reduce the affinity of IGFBP-3 for its receptor. The addition of as little as a twofold molar excess of IGF-I inhibits more than 80% of IGFBP-3 binding to the type V TGF receptor (Leal et al. 1997) , and abrogates the growth inhibition induced by IGFBP-3 in Hs578T cells (Oh et al. 1993b) . In contrast, IGF-I competition for IGFBP-3 receptor binding sites on platelet membranes was extremely weak. As much as a 40 000:1 ratio of IGF-I to 125 I-IGFBP-3 produced hardly more than a 20% reduction in binding to platelet membranes. This is consistent with the observation of Chan & Spencer (1998) , who showed that administration of an IGFBP-3-IGF-I complex to hypophysectomised rats resulted in increased levels of IGFBP-3 and IGF-I in platelet alpha granules. However, this complex was not covalently linked, so retention of the complexed state during binding and internalisation could not be ensured.
The fact that IGF-I had only a minor effect on the binding of IGFBP-3 to its receptor in this study suggests that IGFBP-3 may act as a passive carrier protein for IGF-I, with the intact complex being delivered to the alpha granules. However, a second possibility, i.e. that circulating IGFBP-3-IGF-I complexes dissociate at the cell surface, with IGFBP-3 preferentially binding to its receptor, cannot be excluded on the basis of our results. This finding also indicates that the receptor described in these studies is not the acid-labile subunit (ALS), as IGFBP-3 binding occurs in the absence of an IGF and is not raised by co-incubation with IGF-I. Furthermore, ALS is not detectable in the bone-marrow compartment (data not shown). Studies by Chan & Spencer (1998) indicated that IGFBP-3 is internalised by megakaryocytes, not by circulating platelets, providing further confirmation that the IGFBP-3 receptor is not the ALS.
Another distinguishing feature of the platelet IGFBP-3 receptor is its inability to bind IGFBP-4 in competition with IGFBP-3. This finding is in contrast to the competitive binding of IGFBP-4 shown by Leal et al. (1999) with the type V TGF receptor. Studies by Spencer et al. (1993) showed that, of the six major IGF binding proteins, only IGFBP-3 was located within human platelet alpha granules. In contrast, later studies in rats using a modified alpha-granule lysis technique to avoid heating (Chan & Spencer 1998 ) indicated the presence of low-molecularweight IGF binding proteins in alpha granules, which remained uncharacterised. The inability of rat IGFBP-4 to compete with 125 I-IGFBP-3 for receptor binding sites in the present study suggests three possibilities for the 24 kDa protein observed in rat alpha granules. The 24 kDa band observed may have been a proteolytic fragment of IGFBP-3 resulting from a lack of protease inactivation during alpha-granule lysis. Alternatively, there may be another pathway responsible for IGFBP-4 internalisation, including the possibility of a distinct IGFBP-4 receptor. Another alternative is that human platelet IGFBP-3 receptors may not cross-react with binding proteins from other species.
Our studies could not test whether IGFBP-5 competed with IGFBP-3, because of the large amount of IGFBP-5 required. This interaction is important since IGFPB-5 competes with IGFBP-3 for binding to breast-cancer cell lines (Yamanaka et al. 1999) .
We conclude that an IGFBP-3 receptor is present on megakaryocyte and platelet plasma membranes, where it functions to modulate IGFBP-3 uptake by megakaryocytes and packaging into the alpha granules for subsequent release at sites of platelet lysis. Ongoing investigations of the IGFBP-3 receptor interaction with IGFBP-3 and IGF-I may open the way for therapeutic manipulation of the alpha-granule contents. The use of primary megakaryocytes, or megakaryocytic cell lines shown to express the IGFBP-3 receptor and produce alpha granules, would provide a suitable system in which to examine signalling events involved in the internalisation and storage of IGFBP-3. This system may also reveal other signalling activities, such as modulation of IGFBP-3 or IGF-I receptor expression levels or the induction of growth inhibitory responses similar to those observed in Mv1 Lu and Hs578T cell lines.
